



The Euro-BioImaging Industry Board (EIB) Meeting

January 22nd 2013. 11am – 1pm

Austria Center Vienna (ACV), Bruno-Kreisky-Platz 1, A-1220

Agenda

11.00-12.00 Industry Board meeting (for industry representatives only),
Room O1 J241/1
Chairs: Patrick Schwarb & Horst Hahn

- Welcome and introduction
- Brief summary of recent developments in Euro-BioImaging
- Update on Euro-BioImaging Industry Position Paper
- Discussion on the open call for Nodes from the industry perspective
- Potential role of the EIB during the Euro-BioImaging construction phase
- Miscellaneous

12.00-13.00 Industry partnering Stakeholders (open event)
Room: Foyer

Meeting Summary

The aim of this meeting was to provide to the EIB an overview of Euro-Biolmaging progress, introduce the EIB to new industry participants, updating the ones already involved, and define the role of the EIB during the construction phase of Euro-Biolmaging.

Introduction

Horst Hahn gave an introduction about Euro-Biolmaging general aspects and perspectives, and Patrick Schwarb introduced the EIB Position Paper. It was clarified that the EIB Position Paper is a dynamic document that will be periodically updated. Companies that would like to subscribe the document are invited to send us their company logo that will be included at the next update.

The following points were discussed:

1. Main Contribution of the Industry Board to Euro-Biolmaging

The EIB members are committed to support Euro-Biolmaging towards a **successful, dynamic, and scalable infrastructure** for biomedical imaging in particular, to support Euro-Biolmaging in **leveraging funding** for construction and operation.

2. The EIB concept and role in the Euro-Biolmaging construction phase

Participants agreed that the EIB should have a supporting and consulting role for Euro-Biolmaging but how the EIB will evolve is not yet decided. Different scenarios have been discussed and in the next future the chairs will provide a proposal for the **concept and setup of a future EIB**.

3. Added value for the industry

Industry acknowledges the possibility of using the **Nodes as testing sites** to be very valuable. This is especially true for SMEs, that do not have their own testing sites but also for larger companies to get access to research applications. Also, industry sees the possibility of accessing first hand data on instrument usage at the Euro-Biolmaging Nodes as a valuable source of marketing information. A pipeline to better define the process of testing newly developed technologies at Euro-Biolmaging sites will be developed and is of high interest for both parties. The EIB chairs will iterate with the EIB members on a proposal for **mechanisms** in Euro-Biolmaging that would provide a value to industry.

4. Novel technologies

The Industry Board members appreciate that Euro-Biolmaging is **open for novel technologies** and provides a **platform for validating** them. Companies highlighted that time-to-market requirements in the case of the inclusion of novel, cutting-edge technologies should be taken into consideration.

5. Future plans

The EIB felt the need to improve the **communication** and further discuss the above points. For this reason the EIB chairs proposed two telephone conferences that will be announced. Additionally, the biological imaging industries will take advantage of the ELMI meeting (May 20-24, 2013 in France) to meet up again. Also, in order to reach out for more industries, it was proposed to involve Industries associations. Jens Rietdorf (Zeiss), who launched this proposal, will start contacting some of them in the near future and distribute the EIB Position Paper.

Meeting participants

Patrick Schwarb, Chair

Horst Hahn, Chair

Jan Ellenberg, Euro-BioImaging Scientific Coordinator (attending first half)

Stephan Schoenberg, Euro-BioImaging Scientific Coordinator (attending first half)

Antje Keppler, Euro-BioImaging Project Manager (attending first half)

Pamela Zolda, Euro-BioImaging Project Manager (attending first half)

Marzia Sidri, EIB project manager

John Kleijne, PerkinElmer

Mathias Bach, ImaginOptic

Mark Browne, Andor Technologies

Peter Drent, Nikon

Vim Voorhout, FEI company

Stephanie Teughel, Pepric

Roland Nitschke, GermanBioimaging

Jens Rietdorf, Carl Zeiss Microscopy

Anne Stiebich, Jenoptik

Benedikt Geldmacher, Leica Microsystems

Mathew Issoukis, Leica Microsystems

Attending via con call:

Gitta Hamel, SVI

Beat Lundind, Life Imaging Services

Michelle Malloy, Stratocor

Johannes Gregori, Mediri